BERLDRGPharmaceuticals
Beryl Drugs Ltd — Cash Flow Statement
₹19.28
-9.36%
Beryl Drugs Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.45 Cr | -0.53 Cr | 0.83 Cr | -0.88 Cr | — |
| Repayment Of Debt | -1.91 Cr | -0.25 Cr | -1.92 Cr | -1.99 Cr | — |
| Issuance Of Debt | 1.25 Cr | 0.00 | 1.15 Cr | 2.16 Cr | — |
| Capital Expenditure | -2.19 Cr | -1.35 Cr | -1.56 Cr | -0.42 Cr | — |
| End Cash Position | 0.81 Cr | 0.12 Cr | 0.28 Cr | 0.27 Cr | — |
| Beginning Cash Position | 0.12 Cr | 0.28 Cr | 0.27 Cr | 0.45 Cr | — |
| Changes In Cash | 0.69 Cr | -0.16 Cr | 0.01 Cr | -0.18 Cr | — |
| Financing Cash Flow | -1.55 Cr | 0.10 Cr | -1.20 Cr | -0.24 Cr | — |
| Interest Paid Cff | -0.53 Cr | -0.46 Cr | -0.44 Cr | -0.41 Cr | — |
| Net Issuance Payments Of Debt | -1.02 Cr | 0.55 Cr | -0.77 Cr | 0.17 Cr | — |
| Net Short Term Debt Issuance | -0.36 Cr | 0.80 Cr | -1.80 Cr | 0.48 Cr | — |
| Net Long Term Debt Issuance | -0.66 Cr | -0.25 Cr | 1.03 Cr | -0.31 Cr | — |
| Long Term Debt Payments | -1.91 Cr | -0.25 Cr | -0.12 Cr | -1.99 Cr | — |
| Long Term Debt Issuance | 1.25 Cr | 0.00 | 1.15 Cr | 1.68 Cr | — |
| Investing Cash Flow | -0.40 Cr | -1.08 Cr | -1.18 Cr | 0.52 Cr | — |
| Net Other Investing Changes | 0.13 Cr | -0.07 Cr | 0.28 Cr | 0.94 Cr | — |
| Dividends Received Cfi | 0.00 | 0.00 | 0.00 | — | — |
| Net Investment Purchase And Sale | 0.00 | 0.41 Cr | 0.11 Cr | 0.00 | — |
| Sale Of Investment | 0.00 | 0.41 Cr | 0.11 Cr | 0.00 | — |
| Net PPE Purchase And Sale | -1.28 Cr | -1.33 Cr | -1.56 Cr | -0.42 Cr | — |
| Sale Of PPE | 0.90 Cr | 0.02 Cr | 0.00 | 5000.00 | — |
| Purchase Of PPE | -2.19 Cr | -1.35 Cr | -1.56 Cr | -0.42 Cr | — |
| Operating Cash Flow | 2.64 Cr | 0.82 Cr | 2.39 Cr | -0.47 Cr | — |
| Taxes Refund Paid | -0.18 Cr | -0.20 Cr | -0.06 Cr | -0.03 Cr | — |
| Change In Working Capital | 0.31 Cr | -1.52 Cr | 0.35 Cr | -0.65 Cr | — |
| Change In Other Current Liabilities | -0.27 Cr | -0.08 Cr | 0.06 Cr | -0.17 Cr | — |
| Change In Other Current Assets | -0.08 Cr | 0.60 Cr | 0.56 Cr | 0.13 Cr | — |
| Change In Payable | -0.90 Cr | -1.23 Cr | 0.19 Cr | -0.05 Cr | — |
| Change In Inventory | -0.64 Cr | -0.21 Cr | 1.92 Cr | -0.71 Cr | — |
| Change In Receivables | 2.13 Cr | -0.68 Cr | -2.45 Cr | 0.09 Cr | — |
| Other Non Cash Items | 0.40 Cr | 0.34 Cr | 0.31 Cr | 0.08 Cr | — |
| Depreciation And Amortization | 1.25 Cr | 1.20 Cr | 0.81 Cr | 1.09 Cr | — |
| Depreciation | 1.25 Cr | 1.20 Cr | 0.81 Cr | 1.09 Cr | — |
| Gain Loss On Sale Of PPE | 0.00 | -0.01 Cr | 0.00 | — | — |
| Net Income From Continuing Operations | 0.87 Cr | 1.01 Cr | 0.98 Cr | -0.95 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | 1000.00 | 1000.00 | — | — |
| Net Other Financing Charges | — | 0.01 Cr | 1000.00 | — | 1000.00 |
| Short Term Debt Payments | — | 0.00 | -1.80 Cr | — | -0.04 Cr |
| Short Term Debt Issuance | — | 0.81 Cr | 0.00 | 0.48 Cr | 0.00 |
| Net Intangibles Purchase And Sale | — | 0.02 Cr | 0.00 | — | — |
| Sale Of Intangibles | — | 0.02 Cr | 0.00 | — | — |
| Amortization Cash Flow | — | 3000.00 | 10000.00 | — | — |
| Interest Received Cfi | — | — | — | 0.01 Cr | 0.02 Cr |
| Gain Loss On Investment Securities | — | — | — | — | -0.45 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Beryl Drugs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.